Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. by Nikanjam, Mina et al.
UC San Diego
UC San Diego Previously Published Works
Title
Relationship between protein biomarkers of chemotherapy response and microsatellite 
status, tumor mutational burden and PD-L1 expression in cancer patients.
Permalink
https://escholarship.org/uc/item/5c57730r
Journal
International journal of cancer, 146(11)
ISSN
0020-7136
Authors
Nikanjam, Mina
Arguello, David
Gatalica, Zoran
et al.
Publication Date
2020-06-01
DOI
10.1002/ijc.32661
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Relationship between protein biomarkers of chemotherapy
response and microsatellite status, tumor mutational burden
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1Center for Personalized Cancer Therapy, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center,
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Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between
the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response. Data were extracted
from a clinical-grade testing database (Caris Life Sciences; February 2015 through November 2017): immunotherapy response markers
(microsatellite instability-high [MSI-H], tumor mutational burden-high [TMB-H], and PD-L1 protein expression) and protein
chemotherapy response markers (excision repair complementation group 1 [ERCC1], topoisomerase 1 [TOPO1], topoisomerase
2 [TOP2A], thymidylate synthase [TS], tubulin beta 3 [TUBB3], ribonucleotide reductase regulatory subunit M1 [RRM1] and O-6-methyl
guanine DNA methyltransferase [MGMT]). Relationships were determined by the Mantel-Haenszel chi-squared test or Fischer’s exact
tests. Overall, 28,034 patients representing a total of 40 tumor types were assessed. MSI-H was found in 3.3% of patients (73% were
also TMB-H), TMB-H, 8.4% (28.3% were also MSI-H) and PD-L1 expression in 11.0% of patients (5.1% were also MSI-H; 16.4% were
also TMB-H). Based on concurrent biomarker expression, combinations of immunotherapy with platinum (ERCC1 negativity) or with
doxorubicin, epirubicin or etoposide (TOP2A positivity) have a higher probability of response, whereas combinations with irinotecan or
topotecan (TOPO1 positivity), with gemcitabine (RRM1 negativity), and fluorouracil, pemetrexed or capecitabine (TS negativity) may be
of less benefit. The potential for immunotherapy and taxane (TUBB3 negativity) combinations is present for MSI-H but not TMB-H or
PD-L1-expressing tumors; for temozolomide and dacarbazine (MGMT negative), PD-L1 is frequently coexpressed, but MSI-H and TMB-H
are not associated. Protein markers of potential chemotherapy response along with next-generation sequencing for immunotherapy
response markers can help support rational combinations as part of an individualized, precision oncology approach.
Additional Supporting Information may be found in the online version of this article.
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TOPO1: topoisomerase 1; TS: thymidylate synthase; TUBB3: tubulin beta 3
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What’s new?
With the emerging success of immunotherapy of cancers, combinations with conventional chemotherapies are increasingly
being tested in clinical trials. Here the authors examined concurrent biomarker expression of checkpoint (PD-1/PD-L1) blockade
immunotherapy and various cytotoxic chemotherapies to determine which chemotherapeutic agents will best synergize with
immunotherapy. They predict that combining platinum or doxorubicin, epirubicin, or etoposide treatments with PD-1/PD-L1
inhibitors would have a higher probability of response than other treatments, supporting a rational combination strategy in a
possibly individualized treatment approach.
Introduction
Combinations of immunotherapy and cytotoxic chemotherapy are
increasingly being used and tested in clinical trials.1–3 Chemother-
apy has the potential to enhance antitumor immune responses4
by several mechanisms including activation of immune effectors
such as monocytic-derived dendritic cells5 and sensitizing tumor
cells to lysis.6,7 However, preclinical studies have shown that che-
motherapy can also deplete immunosuppressive cells, including
myeloid-derived suppressor cells8 and T-regulatory cells.9,10 It is
unclear which cytotoxic chemotherapeutic agents will synergize
best with immunotherapy. However, several biomarkers have been
associated with responses to anti-PD-1/PD-L1 checkpoint inhibi-
tors: microsatellite instability high status (MSI-H),11 high tumor
mutational burden (TMB-H),12,13 programmed death-ligand 1
(PD-L1) amplification and increased expression of PD-L1 on
immunohisochemistry.14–18
Protein markers may aid in predicting response or resistance
to specific cytotoxic chemotherapeutic agents (Supporting Infor-
mation Table S1). Elevated topoisomerase 2 (TOP2A) expression
has been linked to doxorubicin response in soft tissue
sarcomas,19 whereas increased topoisomerase 1 (TOPO1) expres-
sion has been associated with response to irinotecan in colorectal
cancer.20 Expression of TOP2A can also predict responses to
etoposide and other anthracyclines.21 High thymidylate synthase
(TS) was associated with decreased response to capecitabine in
metastatic breast cancer,22 whereas low TS was associated with
better response to 5-fluorouracil in colorectal cancer23 and lon-
ger progression-free survival with pemetrexed in nonsmall cell
lung cancer.24,25 Tubulin beta 3 (TUBB3) expression has been
linked to resistance to taxanes in ovarian cancer and lower sur-
vival in prostate cancer.26–28 Expression of excision repair com-
plementation group 1 (ERCC1) negativity predicts improved
response in bladder cancer and longer survival in ovarian and
gastric cancers in with the use of platinum agents.29,30
O-6-methyl guanine DNA methyltransferase (MGMT) defi-
ciency may predict response to dacarbazine in melanoma31 and
temozolomide (glioblastoma and neuroendocrine tumors).32,33
Ribonucleotide reductase regulatory subunit M1 (RRM1) nega-
tivity may predict response to gemcitabine in nonsmall cell lung
cancer.34
The aim of the current study was to determine associations
between protein expression markers of response to chemotherapy
and immunotherapy response markers (MSI-H, TMB-H and
PD-L1 expression) in order to determine which immunotherapy
and chemotherapy combinations could be more likely benefit vari-
ous patient populations.
Materials and Methods
Patient population
Cases submitted to Caris Life Sciences (www.carislifesciences.com),
a Clinical Laboratory Improvement Amendments-certified labora-
tory, between February 2015 and November 2017 that had results
for MSI status, TMB and immunohistochemical (IHC) analysis
(PD-L1, ERCC1, TOPO1, TOP2A, TS, TUBB3, RRM1 and/or
MGMT) were analyzed. Tissue diagnoses were based on pathology
reports from requesting physicians and were verified by a Caris
laboratory-based pathologist. Formalin-fixed paraffin-embedded
tissues were processed as previously described.35 Patient identity
protection was maintained throughout the study and the informa-
tion reflected a deidentified database, so the study was considered
exempt and institutional review board approval was waived.
Techniques for evaluating markers
A variety of technologies were used to evaluate markers and
are summarized in Supporting Information Table S2.
Next-generation sequencing. MSI status and TMB were
determined using next-generation sequencing (NGS) analysis.
NGS was performed on genomic DNA isolated from formalin-
fixed paraffin-embedded tissue using a NextSeq platform
(Illumina Inc., San Diego, CA). An Agilent custom-designed
SureSelectXT assay (Agilent Technologies, Santa Clara, CA) then
was utilized to enrich the 592 whole-gene targets that comprised
the NGS panel (592 genes). All reported variants were detected
with greater than 99% confidence, based on the frequency of the
mutation present and the amplicon coverage. The average depth
of coverage for this assay is ×500 with an analytic sensitivity of
5% variant frequency. To calculate TMB, the number of somatic
nonsilent protein-coding mutations with exclusion of copy num-
ber gene alterations and structural rearrangements were deter-
mined.36 TMB-H was defined as greater than or equal to
17 mutations per megabase (Muts/Mb), TMB-intermediate was
6–16 Muts/Mb, and TMB-low <6 Muts/Mb.
MSI instability by NGS microsatellite loci in the targeted genes
of the panel was first identified using the multiobjective immune
system algorithm (MISA; 8,921 locations identified). Subsequent
analyses excluding sex chromosome loci, microsatellite loci in
regions that typically have lower coverage depth relative to other
3088 Immuno-oncology-chemo response marker associations
Int. J. Cancer: 146, 3087–3097 (2020) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
C
an
ce
r
T
he
ra
py
an
d
P
re
ve
n
ti
on
genomic regions and microsatellites with repeat unit lengths greater
than five nucleotides led to 7,317 target microsatellite loci. After
DNA was sequenced by NGS, the 7,317 target microsatellite loci
were examined and compared with the reference genome hg19 from
the University of California Santa Cruz Genome Browser database.
The number of microsatellite loci that were altered by somatic inser-
tion or deletion was counted for each patient sample and only inser-
tions or deletions that increased or decreased the number of repeats
were considered. A locus was not counted more than once even in
the setting of multiple lengths of insertions or deletions. Thresholds
were calibrated based on a comparison of total number of altered
loci per patient to MSI-fragment analysis results.37
Immunohistochemical analysis. IHC was performed on the
tumor samples using commercially available detection kits and
autostainers (BenchmarkXT, Ventana Medical Systems Inc.,
Santa Clara, CA and Autostainer Link 48, Dako). Primary anti-
bodies used for protein detection were: ERCC1 (8F1) from
Abcam (Cambridge, UK), TOPO1 (1D6) and TOP2A (3F6)
from Leica Microsystems (Buffalo Grove, IL), MGMT (MT21.2)
from Invitrogen (Carlsbad, CA), RRM1 (polyclonal) from Pro-
teintech Group (Rosemont, IL), TS (TS106) from Dako), TUBB3
(PRB-435P) from BioLegend) and PD-L1 (SP142) from Ventana.
The laboratory used staining protocols by Ventana Medical Sys-
tems, Inc. or the Dako (Carpinteria, CA) automated staining sys-
tems. Appropriate positive and negative control specimens were
included for all the antibodies tested. Scoring for all slides was
performed manually by board-certified pathologists with results
reported as a percentage of tumor cells that stained positive and
intensity of staining (0, 1+, 2+ and 3+).
Statistics. All statistical analysis was verified by our biostatisti-
cian (DAB). Associations between MSI status, PD-L1 expression
or TMB status and protein markers (ERCC1, TOPO1, TOP2A,
TS, TUBB3, RRM1 and MGMT) were analyzed with the
Mantel-Haenszel (M-H) chi-square test using tumor type as
stratification. The association between the protein markers and
the presence of any marker predicting response to immunother-
apy (MSI-H, TMB-H or PD-L1 expression) was also determined.
The Breslow-Day test was used to determine if the odds ratios
(OR) for different tumor types were similar such that they could
be combined in the analysis. If the Breslow-Day test was not sig-
nificant (p ≥ 0.05), then the M-H statistic and adjusted OR were
used to describe the data. If the Breslow-Day test was significant
(p < 0.05) then Fisher’s exact test for each tumor type were used
to determine significant relationships and the relationships were
described by ORs in each tumor type separately. p Values less
than or equal to 0.05 were considered significant.
Data availability. The data that support the findings of this
study are available from the corresponding author upon rea-
sonable request.
Results
Data were available for 28,034 patients with MSI status and clas-
sified by 40 cancer types (Table 1; Supporting Information
Table 1. Microsatellite status, tumor mutational burden and protein expression in 28,034 patients1
Positive
(%)
Low or
negative (%)
Number of
patients tested Comment
MSI-H 3.3% 96.7% 28,034 MSI-H is one marker for checkpoint inhibitor immunotherapy response.
Therefore, 3.3% of patients tested for MSI-H status may benefit from
checkpoint inhibitors.11
TMB-H 8.4% 91.6% 27,847 TMB-H is one marker of immunotherapy response.12
PD-L1 11.0% 89.0% 22,114 PD-L1 expression is a marker for immunotherapy response.14
ERCC1 20.9% 79.1% 21,802 ERCC1 negative correlates with platinum response29,30; 79% of patients
tested are ERCC negative/low.
MGMT 55.4% 44.6% 5,200 MGMT negative correlates with dacarbazine/temozolomide response31–33;
45% of patients tested have MGMT negative/low
RRM1 19.9% 80.1% 17,205 RRM1 negative correlates with gemcitabine response34; 80% of patients
tested have RRM1 negative/low.
TOP2A 75.8% 24.2% 12,907 TOP2A positive correlates with doxorubicin,19 etoposide, epirubicin21
response; 76% of patients have TOPO2A high
TOPO1 58.7% 41.3% 22,211 TOPO1 positive correlates with irinotecan and topotecan response20;
59% of patients have TOPO1 positive disease
TS 34.0% 66.0% 20,491 TS negative correlates with fluorouracil/pemetrexed/capecitabine
response22–25; 66% of patients tested have TS negative/low.
TUBB3 56.8% 43.2% 19,863 TUBB3 positive correlates with taxane resistance26–28; 43% of patients
tested have TUBB3 negative/low
1Bolded numbers indicated percentage of patients that may be responsive. No patients had all markers. See also Figure 1 for graphical presentation.
See Materials and Methods section and Supporting Information Table S2 for the methods used in each case to determine positive or negative/low and
Supporting Information Table S1 for the implication of positivity and negativity.
Abbreviations: ERCC1, excision repair complementation group 1; MGMT, O-6-methyl guanine DNA methyltransferase; MSI, microsatellite instability;
RRM1, ribonucleotide reductase regulatory subunit M1; TMB, tumor mutational burden; TOP2A, topoisomerase 2; TOPO1, topoisomerase 1; TS,
thymidylate synthase; TUBB3, tubulin beta 3.
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Tables S3 and S4). Overall, MSI-H was found in 3.3% of patients;
TMB-H, in 8.4% and PD-L1 expression in 11.0% of patients.
TMB-H was found in 2,340 patients; of these, 662 (28.3%) were
also MSI-H and 24.9% of those tested expressed PD-L1. TMB-
intermediate was found in 7,990 patients; of these, 1.6% (125)
were MSI-H. MSI-H was found in 911 patients with a TMB
result; of these 73% (662) were TMB-H (125 patients had TMB-
intermediate and 124 patients, TMB-low) and 15.4% of tested
patients expressed PD-L1. Of the PD-L1 expressing tumors that
were tested for MSI, 5.1% were MSI-H; of the PD-L1 expressing
tumors that were tested for TMB, 16.4% were TMB-H.
Positivity of protein marker expression for all cancers com-
bined was: ERCC1 20.9%, MGMT 55.4%, RRM1 19.9%, TOPO1
58.7%, TOP2A 75.8%, TS 34.0% and TUBB3 56.8% (Table 1). The
percentage of protein expression positivity varied between cancer
types (Supporting Information Table S4). For some of these pro-
teins, for example, ERCC1, RRM1, MGMT, TS and TUBB3, it is
loss of expression that correlates with either sensitivity or less resis-
tance to chemotherapy.23–34 Decreased expression for these pro-
teins was found in the following patients by percent: ERCC1
79.1%, RRM1 80.1%,MGMT 44.6%, TS 66% and TUBB3 43.2%.
MSI-H and chemotherapy protein marker relationships
The relationship between the percentage of patients with protein
expression indicating sensitivity to specific drugs was compared
between MSI-H and MSI-Stable patients (Fig. 1a and Table 2).
TheM-H test was used to compare the likelihood ofMSI-H status
with ERCC1, MGMT, RRM1, TOP2A, TOPO1, TS and TUBB3
expression indicating drug sensitivity (Table 2). Decreased
ERCC1 expression, a marker of potential benefit from platinum
chemotherapy,29,30 was associated with MSI-H status (M-H OR
[95% confidence interval {CI}]: 0.68 (0.55–0.85); p < 0.001). Simi-
larly, low TUBB3 expression (high TUBB3 is a marker of taxane
resistance26–28) was found more commonly in MSI-H patients
(M-H OR 0.71 [0.60–0.83]; p < 0.001). Conversely, decreased
TOPO1 expression (positivity is a marker for likely irinotecan or
topotecan response20) was associated withMSI-H; similarly, RRM1
overexpression (underexpression is a marker of gemcitabine
response34) was more commonly found in with MSI-H patients.
No significant relationship was found between MSI status and
MGMT expression (p = 0.59).
TS and TOP2A could not be evaluated by the M-H test,
which looks at pooled data for all histologies providing that
the individual histologies do not differ significantly from each
other. If the individual histologies differed significantly, we
examined them with the Fisher’s exact test. For TS, the
Fisher’s exact test was significant in 9 of 40 tumor types in
the direction of drug resistance (Supporting Information
Table S5). Specifically TS positivity (reflects 5-fluoruracil resis-
tance22) was associated with MSI-H status in all nine tumor
Figure 1. Protein markers predictive of response to chemotherapy compared with immunotherapy response makers. (a) MSI-H (predictive of
checkpoint inhibitor response) versus MSI-stable. Eighty-eight percent of MSI-H also have ERCC1 negativity (predictive of platinum
response); 44% of MSI-H also have MGMT negativity (predictive of dacarbazine and temozolomide response); 47% of MSI-H also have
RRM1 negative (predictive of gemcitabine response); 93% of MSI-H patients have TOP2A positivity (predictive of with doxorubicin,
epirubicin, etoposide response), 48% of MSI-H patients have TOPO1 positivity (predictive of irinotecan or topotecan response), 33% of
MSI-H patients have TS negativity (predictive of fluorouracil/pemetrexed/capecitabine response) and 53% of MSI-H patients have TUBB3
negativity (predictive of taxane response). (b) TMB-H (predictive of checkpoint inhibitor response) versus TMB-intermediate/-low.
Seventy-six percentage of TMB-H also have ERCC1 negativity (predictive of platinum response); 56% of TMB-H also have MGMT negativity
(predictive of dacarbazine and temozolomide response); 76% of TMB-H also have RRM1 negative (predictive of gemcitabine response);
89% of TMB-H patients have TOP2A positivity (predictive of with doxorubicin, epirubicin and etoposide response), 61% of TMB-H patients
have TOPO1 positivity (predictive of or irinotecan or topotecan response), 61% of TMB-H patients have TS negativity (predictive of
fluorouracil/pemetrexed/capecitabine response) and 29% of TMB-H patients have TUBB3 negativity (predictive of better response to
taxanes). (c) PD-L1 positive (predictive of checkpoint inhibitor response) versus PD-L1 negative. Seventy-five percentage of PD-L1 positive
also have ERCC1 negativity (predictive of platinum response); 52% of PD-L1 positive also have MGMT negativity (predictive of dacarbazine
and temozolomide response); 74% of PD-L1 positive also have RRM1 negative (predictive of gemcitabine response); 86% of PD-L1 positive
patients have TOP2A positivity (predictive of with doxorubicin, epirubicin, etoposide response), 58% of PD-L1 positive patients have
TOPO1 positivity (predictive of irinotecan or topotecan response), 49% of PD-L1 positive patients have TS negativity (predictive of
fluorouracil/pemetrexed/capecitabine response) and 38% of PD-L1 positive patients have TUBB3 negativity (predictive of better response
to taxanes). See Table 2 for additional data.
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types (colorectal [p < 0.001], cholangiocarcinoma [p = 0.022],
epithelial ovarian cancer [p = 0.031], female genital tract
malignancy [p < 0.0001], gastric cancer [p < 0.001], neuroen-
docrine tumor [p = 0.025], cancer with unknown primary
[p < 0.001], pancreatic [p < 0.001] and small intestinal cancers
[p = 0.003]). For TOP2A, Fisher’s exact tests were significant
in 4 of 40 tumor types for drug sensitivity (Supporting Infor-
mation Table S5). TOP2A positivity, a marker of potential
doxorubicin, epirubicin and etoposide benefit,19,21 was signifi-
cantly associated with MSI-H status in all four cancers
(epithelial ovarian [p = 0.0018], female genital tract malignancy
[p = 0.0011], gastric cancer [p = 0.043] and neuroendocrine
tumors [p = 0.0038]).
TMB-H and chemotherapy protein marker relationships
The relationship between the percentage of patients with positive
protein expression indicating sensitivity to specific drugs was com-
pared between TMB-H and TMB-intermediate/-low (Fig. 1b). The
M-H test was used to compare the likelihood of TMB-H status
with ERCC1, MGMT, RRM1, TOP2A, TOPO1, TS and TUBB3
expression indicating drug sensitivity (Table 2). Decreased
ERCC1 expression, a marker of potential benefit from platinum
Table 2. Relationship between protein biomarkers and MSI-H, TMB-H or PD-L1 expression status1
Biomarker
Mantel-Haenszel
odds ratio (95% CI)2 p Value
Number of
patients Potential benefit in combination therapy (yes/no)
Protein markers and MSI-H status
ERCC1 0.68 (0.55–0.85) 0.001 21,772 Yes for benefit of combination of immunotherapy and platinum
(ERCC1 negativity, which is associated with platinum
response,29,30 was correlated with MSI-H).
MGMT 0.91 (0.62–1.30) 0.59 5,175 No significant correlation between MGMT status and MSI-H.
RRM1 3.49 (2.91–4.17) <0.001 17,190 No for benefit of combination of immunotherapy and
gemcitabine (RRM1 negativity is associated with gemcitabine
response.34 However, data show that it is RRM1 positivity that
was correlated with MSI-H).
TOPO1 0.77 (0.67–0.89) 0.001 22,186 No for benefit of combination of immunotherapy and irinotecan
or topotecan. (TOPO1 positivity is associated with irinotecan
response.20 However, data show that TOPO1 negativity was
correlated with MSI-H).
TUBB3 0.71 (0.60–0.83) <0.001 19,839 Yes for benefit of combination of immunotherapy and taxanes
(TUBB3 positivity is associated with taxane resistance.26–28
Data shows that TUBB3 negativity was correlated with MSI-H).
Protein markers and TMB-H status
ERCC1 0.83 (0.72–0.96) 0.013 21,665 Yes for benefit of combination of immunotherapy and platinum
(ERCC1 negativity, which is associated with platinum
response,29,30 was correlated with TMB-H).
MGMT 0.98 (0.80–1.20) 0.86 5,160 No significant correlation between MGMT status and TMB-H.
TOP2A 2.80 (2.15–3.66) <0.001 12,828 Yes for benefit of combination of immunotherapy and
doxorubicin (TOPO2A positivity, which is associated with
doxorubicin, etoposide, epirubicin response,19,21 was
correlated with TMB-H).
TOPO1 0.83 (0.75–0.93) 0.001 22,090 No for benefit of combination of immunotherapy and irinotecan
or topotecan (TOPO1 positivity is associated with irinotecan or
topotecan response.20 However, data shows that it TOPO1
negativity was correlated with TMB-H).
Protein markers and PD-L1 positivity
MGMT 0.78 (0.65–0.95) 0.011 4,919 Yes for benefit of combination of immunotherapy and
temozolomide, dacarbazine. (MGMT negativity, which is
associated with response to dacarbazine31 and
temozolomide,32,33 was correlated with PD-L1 positivity).
TOPO1 1.01 (0.91–1.12) 0.87 18,931 No significant correlation between TOPO1 status and PD-L1
positivity.
1If odds ratio of biomarker is less than 1 and p value is significant, then biomarker negativity is associated with MSI-H or TMB-H. See summary of these
results in Table 3.
2Tumor types were pooled and described in this table by the Mantel-Haenszel odds ratio if the Breslow-Day test was not significant; if the Breslow-Day
test is significant, you cannot pool the tumor types because there are significant differences between histologies. Protein markers with significant
Breslow-Day results were not included in the table, and relationships are summarized in Supporting Information Tables S5–S7.
Abbreviations: CI, confidence interval; ERCC1, excision repair complementation group 1; H, high; MGMT, O-6-methyl guanine DNA methyltransferase;
MSI, microsatellite instability; TMB, tumor mutational burden; TS, thymidylate synthase; TOPO1, topoisomerase 1; TUBB3, tubulin beta 3.
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chemotherapy,29,30 was associated with TMB-H status (M-H OR
[95% CI]: 0.83 [0.72–0.96]; p = 0.013). TOP2A overexpression, a
marker of doxorubicin, etoposide and epirubicin response,19,21 was
found more commonly in TMB-H (M-H OR 2.80 [2.15–3.66];
p < 0.001). No significant relationship was found between TMB
status and MGMT expression (p = 0.86).
RRM1, TS and TUBB3 could not be evaluated by the M-H
test. For RRM1, the Fisher’s exact test was significant in 9 of
40 tumor types (Supporting Information Table S6). RRM1 nega-
tivity, a marker of gemcitabine response,34 was associated with
TMB-H status in nonmelanoma skin cancer (p = 0.031). RRM1
positivity (negativity has been related to gemcitabine response34)
was associated with TMB-H status in eight tumor types: small
intestinal cancer (p = 0.005), pancreatic cancer (p = 0.004), can-
cer with unknown primary (p = 0.010), nonsmall cell lung can-
cer (p = 0.012), female genital tract malignancy (p < 0.001),
epithelial ovarian cancer (p < 0.001), breast cancer (p = 0.040)
and bladder cancer (p = 0.019).
For TS, the Fisher’s exact test was significant in 11 of 40 tumor
types (Supporting Information Table S6). TS negativity, a marker
for fluorouracil, pemetrexed and capecitabine response23–25 was
associated with TMB-H status in two tumor types: breast cancer
(p = 0.029) and Merkel cell cancer (p = 0.048). TS positivity (nega-
tivity is associate with improved responses to 5-flurouracil,
pemetrexed and capecitabine23–25) was associated with TMB-H
status in nine tumor types: small intestinal cancer (p = 0.001),
pancreatic cancer (p = 0.002), cancer with unknown primary
tumors (p = 0.001), nonsmall cell lung cancer (p < 0.001), gastric
cancer (p < 0.001), female genital tract malignancy (p < 0.001),
epithelial ovarian cancer (p = 0.031), cholangiocarcinoma
(p = 0.029) and colorectal cancer (p < 0.001).
For TUBB3, the Fisher’s exact test was significant in 4 of
40 tumor types (Supporting Information Table S6). TUBB3 posi-
tivity, a marker for taxane resistance26–28 was associated with
TMB-H status in two tumor types: nonsmall cell lung cancer
(p = 0.035) and melanoma (p < 0.001). TUBB3 negativity (posi-
tivity is associated with taxane resistance26–28) was associated
with TMB-H status in two tumor types: female genital tract
malignancy (p = 0.039) and colorectal cancer (p = 0.046).
PD-L1 expression and chemotherapy protein marker
relationships
The relationship between the percentage of patients with positive
protein expression indicating drug sensitivity was compared
between PD-L1 expressing tumors and PD-L1 nonexpressing
tumors (Fig. 1c). The M-H test was used to compare the likeli-
hood of PD-L1 expression with ERCC1, MGMT, RRM1, TOP2A,
TOPO1, TS and TUBB3 positivity (Table 2). Decreased MGMT
expression, a marker for temozolomide and dacarbazine
response,31–33 was found more commonly with PD-L1 expression
(M-H OR [95% CI]: 0.78 [0.65–0.95]; p = 0.011). No relationship
was found between TOPO1 and PD-L1 expression (p = 0.87).
ERCC1, RRM1, TOP2A, TS and TUBB3 could not be evalu-
ated by the M-H test. For ERCC1, the Fisher’s exact test was
significant in 4 of 40 tumor types (Supporting Information
Table S7). ERCC1 negativity, a marker of platinum response,29,30
was associated with PD-L1 expression in GIST tumors (p = 0.032),
whereas ERCC1 positivity was associated with PD-L1 expres-
sion in glioblastoma (p = 0.030), female genital tract malignan-
cies (p < 0.001) and esophageal tumors (p = 0.010).
For RRM1, the Fisher’s exact test was significant in 5 of
40 tumor types (Supporting Information Table S7). RRM1 posi-
tivity (RRM1 negativity has been associated with gemcitabine
response34) was associated with PD-L1 expression in nonepithelial
ovarian cancer (p = 0.025), soft tissue sarcoma (p = 0.010), pancre-
atic cancer (p = 0.032), female genital tract malignancy (p = 0.016)
and cholangiocarcinoma (p = 0.002).
For TOP2A, the Fisher’s exact test was significant in 10 of
40 tumor types (Supporting Information Table S7). TOP2A positiv-
ity, a marker of doxorubicin, etoposide and epirubicin response,19,21
was associated with PD-L1 expression in nonepithelial ovarian can-
cer (p = 0.029), soft tissue sarcoma (p < 0.001), cancer with
unknown primary (p < 0.001), nonmelanoma skin cancer
(p = 0.045), nonsmall cell lung cancer (p < 0.001), neuroendocrine
tumors (p = 0.003), mesothelioma (p = 0.013), kidney cancer
(p < 0.001), head and neck cancer (p = 0.001) and female genital
tract malignancy (p < 0.001).
For TS, the Fisher’s exact test was significant in 15 of
40 tumor types (Supporting Information Table S7). TS positiv-
ity (TS negativity has been associated with fluorouracil,
pemetrexed and capecitabine response23–25) was associated
with PD-L1 expression in small intestinal cancer (p = 0.007),
pancreatic cancer (p < 0.001), cancer with unknown primary
(p < 0.001), nonsmall cell lung cancer (p = 0.036), neuroendo-
crine tumors (p = 0.035), melanoma (p = 0.006), kidney cancer
(p = 0.015), head and neck cancers (p < 0.001), gastric cancer
(p < 0.001), female genital tract malignancy (p = 0.031), epithe-
lial ovarian cancer (p = 0.008), cholangiocarcinoma (p = 0.006),
colorectal cancer (p < 0.001), breast cancer (p < 0.001) and
bladder cancer (p = 0.001).
For TUBB3, the Fisher’s exact test was significant in 8 of
40 tumor types (Supporting Information Table S7). TUBB3 positiv-
ity, a marker for taxane resistance,26–28 was associated with PD-L1
expression in soft tissue sarcoma (p = 0.027), cancer with unknown
primary tumors (p = 0.019), nonsmall cell lung cancer (p < 0.001),
kidney cancer (p = 0.006), head and neck cancer (p = 0.035), gastric
cancer (p = 0.001), esophageal cancer (p = 0.004) and bladder can-
cer (p = 0.001).
Discussion
Activating the immune system to fight metastatic malignan-
cies has been a major breakthrough in cancer therapy particu-
larly for melanoma and lung cancer. Given the heterogeneity
and complexity of metastatic solid tumors,38–41 it is important
to give cancer therapy in combinations. Cytotoxic chemother-
apy has the potential to augment the immune response and
improve response rates and outcomes. However, cytotoxic che-
motherapy can also have negative effects, including toxicities
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and immune cell depletion. It is unclear which chemotherapeu-
tic agents would be most frequently effective when combined
with checkpoint inhibitor immunotherapy.
The current study explored relationships between markers of
chemotherapy response and of response to anti-PD1/PD-L1
immunotherapy, such as MSI-H, TMB-H and PD-L1 expres-
sion.11,12,14 The overall findings are summarized in Table 3.
ERCC1 negativity, a marker of platinum response,29,30 was fre-
quently correlated with both MSI-H and TMB-H status in the
pooled analysis of tumors but was not correlated with PD-L1
IHC-positive status across tumor types. Overall, this would pre-
dict a potential benefit for immunotherapy and platinum agent
combinations in patients with MSI-H or TMB-H. MGMT nega-
tivity correlated with PD-L1 expression but was not significantly
correlated with MSI-H and TMB-H evaluations. This would pre-
dict a potential benefit for dacarbazine or temozolomide31–33
combined with checkpoint inhibitors in patients whose tumors
expressed PD-L1 by IHC but not necessarily in those with
MSI-H or TMB-H. RRM1 positivity (negativity is a biomarker
for gemcitabine response34) was associated with MSI-H. This
relationship was also found for many tumor types with TMB-H
and PD-L1, suggesting that gemcitabine would not benefit most
of these patients in combination with checkpoint blockade
immunotherapy. TOP2A positivity, which predicts response to
doxorubicin, epirubicin and etoposide,19,21 was associated with
TMB-H. This relationship was also found for many tumor types
with MSI-H and PD-L1. TOPO1 negativity correlated with
MSI-H and TMB-H, but TOPO1 levels were not significantly
associated with PD-L1 expression. As TOPO1 negativity suggests
lack of response to irinotecan and topotecan (positivity is predic-
tive of response20), these data indicate infrequent benefit from
combining anti-PD-1/PD-L1 agents with irinotecan or topotecan.
TS positivity, a marker of attenuated response to fluorouracil,
pemetrexed or capecitabine,22–25 correlated with MSI-H, TMB-H
and PD-L1 in many tumor types; thus, combinations involving
fluorouracil, pemetrexed or capecitabine and immunotherapy are
less likely to be of benefit. TUBB3 negativity, a marker of taxane
response,26–28 was associated with MSI-H, whereas negativity
(taxane resistance) was related to PD-L1 in many tumor types;
thus, the benefit for combining taxanes with immunotherapy is
likely to be more frequent in patients with MSI-H and less fre-
quent in those with PD-L1 expression (Table 3).
Prior studies of the relationships between protein markers and
response to cytotoxic chemotherapy were performed in a disease-
specific manner. These studies evaluated commonly used chemo-
therapeutic agents for each cancer type. However, these relation-
ships may hold for other cancer types.21,42 In our study, although
many of the statistical relationships determined were valid across
tumor types, most of the PD-L1 assessments and all TS relation-
ships were evaluated by individual tumor type as the significant
differences between tumor types did not allow for pooling. Thus,
any relationships found only held for a subset of the tumor types
evaluated. In some cases, the lack of significance for other tumor
types may be due to lack of power for the individual tumor types.
Prior oncology therapeutics and regimens were approved by the
Food and Drug Administration (FDA) and administered based on
tissue of origin of the tumor. However, recent advances in NGS and
molecular profiling have demonstrated that each tumor has a
unique molecular profile, which mandates a more personalized
approach.39,40,43 Recent studies have explored dosing of novel com-
binations of targeted agents, cytotoxics and immunotherapies.3,44–46
The FDA recently approved pembrolizumab in a tissue-agnostic
manner for use in all patients with MSI-H status or mismatch gene
alterations,47 which signifies a major shift in drug approval practice.
Additional studies have suggested that patients with high TMB12 or
PD-L1 expression14 will have superior responses to checkpoint
blockade immunotherapy. Although cytotoxic chemotherapy has
also traditionally been administered based on tumor of origin, more
recent data19–34 support the use of protein markers to provide
insight into how best tomatch these agents to an individual patient.
All patients would ideally have molecular profiling including
MSI, TMB, PD-L1 and protein marker information prior to the
start of therapy, but due to delays in acquiring tissue from pathol-
ogy and conducting NGS, patients may not have a full genomic
and protein marker profile at the start of treatment. This is espe-
cially true for a patient who needs urgent initiation of therapy due
to organ failure from malignancy. Immunotherapy and chemo-
therapy combinations are increasingly being studied in clinical tri-
als; thus, a better understanding of the relationships between
markers of response to chemotherapy and immunotherapy—in
particular, which combinations will give a higher probability of
response—as evaluated in the current study, is essential.
Other findings of interest also emerged from out interrogation
of tissue markers. MSI-H status was only observed in 3%, whereas
TMB-H was seen in 8.4% of the patients reviewed and PD-L1
expression was present in 11.0% patients in the current study. Other
studies have shown corresponding percentages of 7.1% (TMB-H)48
and 3.5% (MSI-H).49 In the current study, only 28% of patients
with TMB-H status had concurrent MSI-H; however, the majority
of patients with MSI-H status were TMB-H (73%). A prior study of
TMB across tumor types showed that 83% of patients with MSI-H
status had TMB-H; however, only 16% of TMB-H patients had
MSI-H status.48 Given that MSI-H, TMB-H and PD-L1 expression
often do not cooccur, it is not surprising that the current study often
found distinct relationships between each of these three immuno-
therapy markers and the protein markers.
This study had several important limitations. First, the
database was deidentified; hence, future studies will need to
determine if these relationships correlate with better outcomes
for the cognate combinations. Some markers can be evaluated
by more than one methodology, and precise-points for impor-
tant markers such as TMB-H are still a matter of debate. Third,
the markers of response to chemotherapy were assumed to hold
for all tumor types; however, they may not have been validated
in all tumor types. Of note, ERCC1 has not been found to be
predictive of nonsmall cell lung cancer responses to platinum
agents50; thus, we did not evaluate ERCC1 relationships
with MSI, TMB and PD-L1 in nonsmall cell lung cancer.
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Furthermore, a significant M-H test indicates that a relation-
ship exists between immunotherapy and chemotherapy
response markers when taking into account possible con-
founding from the different tumor types, but does not mean
there is a relationship present for each individual tumor type.
The study aimed to make overall conclusions regarding immu-
notherapy and chemotherapy response marker associations to
provide clinically useful information to help guide precision
medicine treatments and clinical trials. Fourth, the mechanisms
underlying the associations described in this report are not
clear. Fifth, specific treatments might result in a change in
expression of PD-L1 or other markers as the tumor evolves.
Finally, the ability of protein markers to predict chemotherapy
response is still not considered as robust as the predictive
power of NGS for immunotherapy or gene-targeted agents.
In conclusion, MSI-H, TMB-H and PD-L1 expressions were
found to correlate with specific protein markers of response to che-
motherapy. Based on the cooccurrence of these biomarkers, combi-
nations of PD1/PD-L1 checkpoint inhibitor immunotherapy with
temozolomide, dacarbazine, doxorubicin, epirubicin, etoposide and
platinum will have a higher probability of a response, whereas
combinations of immunotherapy with irinotecan, topotecan,
gemcitabine, fluorouracil, pemetrexed and capecitabinemay less fre-
quently have salutary effects. Taxanes may be of more frequent ben-
efit to patients with MSI-H but not those with TMB-H or PD-L1
expression. Protein markers of chemotherapy response along with
NGS for immunotherapy response markers should be evaluated in
prospective trials to determine if these markers can help support the
rational use of chemotherapy as part of an individualized, precision
medicine approach to oncology therapy.
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